Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2–3 …
…, A Xu, S Cang, C Du, Q Li, Y Lu, Y Chen, Y Guo… - The Lancet …, 2021 - thelancet.com
Background China has a high burden of hepatocellular carcinoma, and hepatitis B virus (HBV)
infection is the main causative factor. Patients with hepatocellular carcinoma have a poor …
infection is the main causative factor. Patients with hepatocellular carcinoma have a poor …
Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international …
…, S Gu, Y Bai, Z Ren, X Lin, Z Chen, W Jia, Y Jin, Y Guo… - The Lancet, 2023 - thelancet.com
Background Immunotherapy with immune checkpoint inhibitors combined with an anti-angiogenic
tyrosine-kinase inhibitor (TKI) has been shown to improve overall survival versus anti-…
tyrosine-kinase inhibitor (TKI) has been shown to improve overall survival versus anti-…
[HTML][HTML] aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitis
…, Y Zhou, Z Zhang, M Buti, SJ Hutchinson, Y Guo… - Journal of …, 2020 - Elsevier
Background & Aims Hepatocellular carcinoma (HCC) is the leading cause of death in patients
with chronic hepatitis. In this international collaboration, we sought to develop a global …
with chronic hepatitis. In this international collaboration, we sought to develop a global …
Quantitative analysis of HBV DNA level and HBeAg titer in hepatitis B surface antigen positive mothers and their babies: HBeAg passage through the placenta and the …
…, J Zhang, H Yang, X Li, S Wen, Y Guo… - Journal of medical …, 2003 - Wiley Online Library
It is well documented that perinatal transmission is the major cause of chronic HBV infection
in China. However, the mechanisms of HBV perinatal transmission are not defined clearly. It …
in China. However, the mechanisms of HBV perinatal transmission are not defined clearly. It …
Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open …
…, V Marquez, M Brahmania, Q Li, B Xing, Y Guo… - The Lancet, 2023 - thelancet.com
Background No adjuvant treatment has been established for patients who remain at high
risk for hepatocellular carcinoma recurrence after curative-intent resection or ablation. We …
risk for hepatocellular carcinoma recurrence after curative-intent resection or ablation. We …
ACP risk grade: a simple mortality index for patients with confirmed or suspected severe acute respiratory syndrome coronavirus 2 disease (COVID-19) during the …
…, Q Liu, H Li, J Sun, J Peng, X Yi, Z Zhou, Y Guo… - MedRxiv, 2020 - medrxiv.org
Background Since the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
disease (COVID-19) outbreaks in Wuhan, China, healthcare systems capacities in highly …
disease (COVID-19) outbreaks in Wuhan, China, healthcare systems capacities in highly …
Tislelizumab vs sorafenib as first-line treatment for unresectable hepatocellular carcinoma: a phase 3 randomized clinical trial
S Qin, M Kudo, T Meyer, Y Bai, Y Guo, Z Meng… - JAMA …, 2023 - jamanetwork.com
Importance Hepatocellular carcinoma (HCC) is a leading cause of cancer-related mortality,
and additional first-line treatments are needed. The programmed cell death protein 1 …
and additional first-line treatments are needed. The programmed cell death protein 1 …
Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial
…, K Gu, X Chen, T Zhang, C Hao, P Cao, Y Guo… - The Lancet …, 2023 - thelancet.com
Background Systemic therapies have improved the management of hepatocellular carcinoma,
but there is still a need to further enhance overall survival in first-line advanced stages. …
but there is still a need to further enhance overall survival in first-line advanced stages. …
Guidelines for the diagnosis and treatment of primary liver cancer (2022 edition)
…, Y Chen, W Cheng, S Cheng, C Dai, W Guo, Y Guo… - Liver Cancer, 2023 - karger.com
Background: Primary liver cancer, of which around 75–85% is hepatocellular carcinoma in
China, is the fourth most common malignancy and the second leading cause of tumor-related …
China, is the fourth most common malignancy and the second leading cause of tumor-related …
Baveno VI criteria and spleen stiffness measurement rule out high-risk varices in virally suppressed HBV-related cirrhosis
…, B Wen, X Chang, Q Wu, W Wen, F Zhou, Y Guo… - Journal of …, 2021 - Elsevier
Background & Aims There are no data validating the performance of spleen stiffness measurement
in ruling out high-risk varices in patients with HBV-related cirrhosis under maintained …
in ruling out high-risk varices in patients with HBV-related cirrhosis under maintained …
